310 Mira Street, Stavropol, Russia, 355017
+7 8652 352524; +7 8652 353229.
+7 8652 352524.
The journal is included into The list of leading scientific periodicals.
At the study was to evaluate immune response to HBV vaccine in Health care workers (HCWs) and detect risk factors of non-responsible persons. Descriptive retrospective analyses of antibodies’ titer dynamics in 98 HBV vaccinated HCWs conducted from 1998 to 2011 years annually were evaluated by measuring serum HBsAb levels, by objective state and on the main laboratory results taken in medical documents. After vaccination negative response (аHBs<10 mIU/ml) was in 20.4 %, poor immune response (аHBs>10 mIU/ml<100 mIU/ml) – in 34.7 % and high immune response (аHBs>100 mIU/ml) – in 44.9 % HCWs. Оbesity, insulin resistance, аge over 40 years, male gender and low level of 25(OH)D were associated with negative response to vaccination. In titer аHBs<100 mIU/ml, patients became seronegative in three years after vaccination. In high immune response, patients stay seropositive during 10 years. The introduction of a booster dose of the vaccine and activating cellular immunity, can improve the immunogenicity of the vaccine. Thus оbesity insulin resistance, inadequate supply of 25 (OH)D, аge over 40 years and male gender were associated with non response to vaccination. It’s necessary to follow-up of the primary immune response in HCWs in order to specify the additional doses of the vaccine in seronegative patients.
1. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of Hepatitis B vaccines: Implications for persons at occupational risk of Hepatitis B virus infection Am J Prev Med. 1998;15(1):73-77.
2. Dannetun E., Teqneu A., Torner A., Giesecke J. Coverage of hepatitis B vaccination in Swedish health care workers. J Hosp Infect. 2006;63(2):201-204.
3. Estevez Z. C., Betancourt A. A., Muzio G. V., Baile N. F., Silva C. V., Bernal F. H. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals. 2007;35(2):115-122.
4. Hepatitis B vaccines. Weekly Epidemiological Record 2009;84(40):405-420.
5. Hollinger E. B., Kim C. N., Lee H. U. Factor influencing the immune response to hepatitis B Vaccine, booster dose Guideline and vaccine Protocol recommendation. Am J Med. 1989;16:365-403.
6. Health care personnel vaccination recommendations. Immunization Action Coalition. Technical content reviewed by the Centers for Disease Control and prevention, October 2009. http://www.immunize.org/catg.d/p 2017.pdf
7. Resolution of the Chief State Sanitary Doctor of the Russian Federation on May 30, 2012 N ‘34 Moscow «On measures aimed at the elimination of acute hepatitis B in the Russian Federation http://www.rg.ru/2012/07/06/onishenko-dok.html
8. Immunization of Health care workers. Recommendation of advisory committee on immunization practice (ACIP) and the Hospital Infection Control Practice Advisory committee (HICPAC). MMWR, Recommendation and report 26: 12/26/97.
9. Jack A. D., Hall A. J., Maine N., Meudy M., Whittle H. C. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179:489-492.
10. Kane A., Lloyd J., Zaffran M., Simonsen L., Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ. 1999;(77):801-807.
11. Kao J. H., Chen D. S. Overview of Hepatitis B and C virus. In Infectious cause of cancer: target for intervention. Edited by: Guerdon T. J. J., Totowa N. J.: Humana press. 2000: 313-330.
12. Lasemi E., Haddadpour N., Navi F., Rakhshan A., Rakhshan V. Rate of Acquired Immunity in Dental Students after Hepatitis B Vaccination. Dent Res J. 2011;8(3):128-131.
13. Louther J., Feldman J., Rivera P., Villa N., DeHovitz J., Sepkowitz K. A. Hepatitis B vaccination program at a New York City hospital: Seroprevalence, seroconversion, and declination. Am J Infect Control. 1998;26(4):423-427.
14. Luiz A. S., Ciorlia I., Dirce M.T. Zanetta Hepatitis B in Health Care workers: Prevalence, vaccination and relation to occupational factor. The Brazilian journal of infectious disease. 2005;9(5):384-389.
15. Lupberger J., Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol. 2007;13:74-81.
16. Platkov E., Shlyakhov E., Glick Y., Khalemsky S., Fischbein A. Immunologic evaluation of hepatitis B vaccine application in hospital staff . Int J Occup Med Environ Health. 2003;16(3):249-253.
17. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A. A. et al. Seroprotection of hepatitis B vaccine and need for booster dose: a metaanalysis. Journal of Hepatitis Monthly. 2009;9(4):293-304.
18. Roome A. J., Walsh S. J., Catter M. L., Haddle J. L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 1993;70:2931-2934.
19. WHO: Fact sheet 204;Hepatitis B.2015. URL:http://www/who.int/ mediacentre/ factsheets/ fs204/en/index.html.
20. Zeeshan M., Jabeen K., Nausheen A., Akbar A., Wilayat A. A. et al. Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study. BMC Infectious Diseases. 2007;7:120.
Keywords: вакцинация, иммунный ответ, вирусный гепатит В, инсулинорезистентность, ожирение, работники здравоохранения